{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:53:44Z","timestamp":1790538824940,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T00:00:00Z","timestamp":1583884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>The prognosis of lymphoma that occurs in patients with inflammatory bowel disease [IBD] is poorly known.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A multicentre retrospective cohort analysis was done in seven French tertiary centres from 1999 to 2019. Only lymphoma occurring in patients with previous established diagnosis of IBD were analysed. The primary outcome was progression-free survival at 3 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 52 patients [male 65%, Crohn\u2019s disease 79%, median age 48.3 years, median duration of IBD 10.1 years] were included, of whom 37 had been previously exposed to immunosuppressants and\/or biologics for at least 3 months and 20 had primary intestinal lymphomas. The lymphoma histological types were: diffuse large B cell lymphomas [N\u2005=\u200517], Hodgkin lymphomas [N\u2005=\u200517], indolent B cell lymphomas [N\u2005=\u200512], and others including T cell lymphomas, mantle cell lymphomas, and unclassifiable B cell lymphoma [N\u2005=\u20056]. The median follow-up after lymphoma was 5.1 years (interquartile range [IQR] 4\u20137.8). Progression-free survival at 3 years was 85% in the overall population (95% confidence interval [CI] 75%\u201396%) with no significant difference between the exposed and unexposed group, 79% for patients exposed to immunosuppressants and\/or biologics [95% CI 67%\u201394%], and 83% for patients diagnosed with primary intestinal lymphoma [95% CI 67%\u2013100%]. No relapse of IBD has been observed during chemotherapy. The IBD relapse rate at the end of the last chemotherapy cycle was 23% at 3 years [95% CI 11%-39%] in the overall population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this large cohort, the prognosis for lymphomas occurring in IBD appears to be good and similar to what is expected, irrespective of the exposure to biologics and\/or immunosuppressants.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaa048","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T20:22:35Z","timestamp":1583785355000},"page":"1222-1230","source":"Crossref","is-referenced-by-count":12,"title":["Prognosis of Lymphoma in Patients With Known Inflammatory Bowel Disease: A French Multicentre Cohort Study"],"prefix":"10.1093","volume":"14","author":[{"given":"T","family":"Severyns","sequence":"first","affiliation":[{"name":"Service de Gastroent\u00e9rologie, H\u00f4pital Saint Louis, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Kirchgesner","sequence":"additional","affiliation":[{"name":"Service de Gastroent\u00e9rologie, H\u00f4pital Saint-Antoine, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Lambert","sequence":"additional","affiliation":[{"name":"Service de Biostatistiques et Information M\u00e9dicale, H\u00f4pital Saint-Louis, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9mato-oncologie, H\u00f4pital Saint-Louis, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Amiot","sequence":"additional","affiliation":[{"name":"Service de Gastroent\u00e9rologie, H\u00f4pital Henri Mondor, UPEC, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Abitbol","sequence":"additional","affiliation":[{"name":"Service de Gastroent\u00e9rologie, H\u00f4pital Cochin, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Treton","sequence":"additional","affiliation":[{"name":"Service de Gastroent\u00e9rologie, H\u00f4pital Beaujon, Universit\u00e9 de Paris, Clichy La Garenne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Cazals-Hatem","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pathologie, H\u00f4pital Beaujon, Universit\u00e9 de Paris, Clichy La Garenne. France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Malamut","sequence":"additional","affiliation":[{"name":"Service de Gastroent\u00e9rologie, H\u00f4pital Europ\u00e9en Georges Pompidou, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Coppo","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, H\u00f4pital Saint-Antoine, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Galicier","sequence":"additional","affiliation":[{"name":"Service d\u2019Immunoh\u00e9matologie, H\u00f4pital Saint Louis, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Walter-Petrich","sequence":"additional","affiliation":[{"name":"Service de Biostatistiques et Information M\u00e9dicale, H\u00f4pital Saint-Louis, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Deau-Fischer","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, H\u00f4pital Cochin, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Besson","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie-Oncologie, Centre Hospitalier de Versailles, Universit\u00e9 Versailles Saint Quentin en Yvelines, Universit\u00e9 de Paris-Saclay, Le Chesnay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Aparicio","sequence":"additional","affiliation":[{"name":"Service de Gastroent\u00e9rologie, H\u00f4pital Saint Louis, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Beaugerie","sequence":"additional","affiliation":[{"name":"Service de Gastroent\u00e9rologie, H\u00f4pital Saint-Antoine, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Allez","sequence":"additional","affiliation":[{"name":"Service de Gastroent\u00e9rologie, H\u00f4pital Saint Louis, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Gornet","sequence":"additional","affiliation":[{"name":"Service de Gastroent\u00e9rologie, H\u00f4pital Saint Louis, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,11]]},"reference":[{"key":"2020091607141557000_CIT0001","doi-asserted-by":"crossref","first-page":"1756284819853208","DOI":"10.1177\/1756284819853208","article-title":"New biologics and small molecules in inflammatory bowel disease: an update","volume":"12","author":"Sabino","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"2020091607141557000_CIT0002","article-title":"Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis","author":"Singh","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020091607141557000_CIT0003","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"2020091607141557000_CIT0004","first-page":"195","article-title":"Cancers complicating inflammatory bowel disease","volume":"373","author":"Beaugerie","year":"2015","journal-title":"N Engl J Med"},{"key":"2020091607141557000_CIT0005","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1111\/j.1572-0241.2000.02316.x","article-title":"Risk of lymphoma in inflammatory bowel disease","volume":"95","author":"Loftus","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"2020091607141557000_CIT0006","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020091607141557000_CIT0007","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"2020091607141557000_CIT0008","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A systematic review of factors that contribute to hepatosplenic T cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020091607141557000_CIT0009","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/ibd.22889","article-title":"Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease","volume":"18","author":"Sokol","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2020091607141557000_CIT0010","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/ibd.22866","article-title":"Prognosis of lymphoma in patients following treatment with 6-mercaptopurine\/azathioprine for inflammatory bowel disease","volume":"18","author":"Sultan","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2020091607141557000_CIT0011","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"2020091607141557000_CIT0012","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B cell lymphoma: a randomised controlled trial by the MabThera International Trial [MInT] Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"2020091607141557000_CIT0013","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.15622","article-title":"Current treatment paradigms for advanced stage Hodgkin lymphoma","volume":"184","author":"Longley","year":"2019","journal-title":"Br J Haematol"},{"key":"2020091607141557000_CIT0014","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11912-019-0808-0","article-title":"Follicular lymphoma: diagnostic and prognostic considerations in initial treatment approach","volume":"21","author":"Boughan","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"2020091607141557000_CIT0015","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/cam4.763","article-title":"Gastrointestinal follicular lymphoma: using primary site as a predictor of survival","volume":"5","author":"Chouhan","year":"2016","journal-title":"Cancer Med"},{"key":"2020091607141557000_CIT0016","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B cell lymphomas: a randomised controlled trial [RICOVER-60]","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"2020091607141557000_CIT0017","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"2020091607141557000_CIT0018","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.crohns.2013.12.022","article-title":"Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease","volume":"8","author":"Rajca","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2020091607141557000_CIT0019","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00000478-200001000-00008","article-title":"Epstein-Barr virus-positive primary gastrointestinal Hodgkin\u2019s disease: association with inflammatory bowel disease and immunosuppression","volume":"24","author":"Kumar","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"2020091607141557000_CIT0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2018.06.008","article-title":"Hodgkin lymphoma of the gastrointestinal tract in patients with inflammatory bowel disease: portrait of a rare clinical entity","volume":"71","author":"Barzilai","year":"2018","journal-title":"Leuk Res"},{"key":"2020091607141557000_CIT0021","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/ibd.21487","article-title":"Clinical course of Crohn\u2019s disease following treatment of lymphoma","volume":"17","author":"El Mourabet","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2020091607141557000_CIT0022","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/j.gastro.2015.08.055","article-title":"Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease","volume":"149","author":"Torres","year":"2015","journal-title":"Gastroenterology"},{"key":"2020091607141557000_CIT0023","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2468-1253(17)30056-0","article-title":"Autologous stem-cell transplantation in treatment-refractory Crohn\u2019s disease: an analysis of pooled data from the ASTIC trial","volume":"2","author":"Lindsay","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020091607141557000_CIT0024","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"2020091607141557000_CIT0025","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti\u2013tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: a meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020091607141557000_CIT0026","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1053\/j.gastro.2013.07.035","article-title":"Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study","volume":"145","author":"Khan","year":"2013","journal-title":"Gastroenterology"},{"key":"2020091607141557000_CIT0027","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"JAMA"},{"key":"2020091607141557000_CIT0028","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/ajg.2011.479","article-title":"Lymphoma in inflammatory bowel disease and treatment decisions","volume":"107","author":"Bewtra","year":"2012","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaa048\/33009700\/jjaa048.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/9\/1222\/33751681\/jjaa048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/9\/1222\/33751681\/jjaa048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T11:39:06Z","timestamp":1600256346000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/14\/9\/1222\/5803309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,11]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,3,11]]},"published-print":{"date-parts":[[2020,9,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa048","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9,1]]},"published":{"date-parts":[[2020,3,11]]}}}